Budesonide suspension combined with compound ipratropium bromide in treatment of acute exacerbation of chronic obstructive pulmonary disease

Objective To study the effectiveness of budesonide suspension combined with compound ipratropium bromide in the treatment of acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Methods Patients with AECOPD were enrolled from April 2016 to April 2018 in our hospital, and randomly divided into control group and observation group with 53 cases in each group. All patients received routine comprehensive treatment to control infection, relieve cough, reduce sputum, and relieve asthma. On this basis, the observation group received atomized inhalation of compound ipratropium bromide and budesonide suspension. The total effective rate, time to symptoms and signs disappearing, pulmonary function and arterial blood gas level before and after treatment were compared between two groups. Results The total effective rate of observation group was 94.34%, which was significantly higher than that of control group (75.47%) (χ²=7.36, P=0.00). The time to symptoms and signs disappearing in observation group was significantly lower than that of control group cough, (2.17±0.75) d vs (3.55±0.82) d; shortness of breath, (2.63±0.86) d vs (4.30±0.95) d; wheezing, (2.72±0.87) d vs (4.76±1.41) d; rale of lung, (4.88±1.03) d vs (7.05±1.74) d(all P＜ 0.05). After treatment, the pulmonary function indexes such as FEV₁, FEV₁/FVC and PEF in the observation group were significantly higher than the control group FEV₁, (1.98±0.63) L vs (1.73±0.56) L; FEV₁/FVC, (72.47±6.69)% vs (60.93±6.85)%; PEF, (6.08±1.20) L/s vs (5.11±1.04) L/s, all P＜ 0.05, and the level of PaCO₂ in arterial blood was significantly lower than the control group (43.08±4.76) mmHg vs (52.26±5.49) mmHg, P＜ 0.05. The level of PaO₂ in the obsercation group was significantly higher than that in the control group (81.05±8.23) mmHg vs (69.13±7.46) mmHg, P ＜ 0.05. Conclusion Budesonide suspension combined with compound ipratropium bromide atomization inhalation is effective in the treatment of AECOPD. It can promote the recovery of symptoms and signs, correct the disorder of arterial blood gas and improve the pulmonary function of patients, which is worthy of popularizing in clinical practice.